Robotic Platforms & Manufacturers
Robotic systems differ in access, instruments, feedback, approved procedures and service requirements. Authorization is specific to a model, indication, patient group and jurisdiction; a platform's use in an overseas series does not establish US clearance for the same operation. This overview identifies clinically relevant distinctions and selected verified regulatory changes, rather than ranking manufacturers by marketing claims.
See Reconstructive Applications for outcome evidence and Single-Port Robotics for access planning.
Platform Overview
| Platform / manufacturer | Architecture and distinguishing features | Regulatory or interpretation point |
|---|---|---|
| da Vinci X / Xi / 5 — Intuitive | Multiport systems with surgeon console and patient cart. Xi has boom rotation; X shares much of the Xi instrument ecosystem but does not have that rotating boom. Da Vinci 5 supports dedicated Force Feedback instruments. | Instruments, software, use limits and approved procedures are generation-specific; Si is a distinct legacy system.[1][2] |
| da Vinci SP — Intuitive | One 25 mm cannula accommodates a flexible endoscope and three jointed instruments. | Single-port access is a different instrument/working-space architecture, not merely clustering Xi trocars. See the dedicated page for approach and label limits.[3] |
| Hugo RAS — Medtronic | Modular arm carts and an open 3D console. | FDA clearance for adult urologic procedures announced December 3, 2025, including prostatectomy, nephrectomy and cystectomy. The current US indication page specifies trained physicians and the system's indications document.[4] |
| Versius / Versius Plus — CMR Surgical | Modular bedside units; open console with choice of working position; wristed instruments. | First-generation US De Novo authorization was October 2024 for cholecystectomy in adults ≥22 years, not general authorization for all soft-tissue surgery. Current US Versius Plus labeling also specifies cholecystectomy; a submission for another specialty is not clearance.[5] |
| DEXTER — Distalmotion | Allows switching between laparoscopic and robotic work; open console and separately positioned robotic units. | US indications have expanded beyond its original inguinal-hernia authorization. June 16, 2026 clearance includes sacrocolpopexy, sacrocervicopexy, sacrohysteropexy and endometriosis resection; the exact current instructions still govern use.[6] |
| Senhance — Asensus / KARL STORZ | Haptic feedback and eye-tracking are features of the Senhance lineage. | KARL STORZ acquired Asensus in August 2024. The current manufacturer notice says Senhance will be discontinued, with support/transition arrangements communicated to customers. This is a legacy platform, not the only available force-feedback option.[7] |
| avatera — avateramedical | Four-arm system; 5 mm instruments, manufacturer-described seven degrees of freedom and single-use instruments/sterile accessories. | The manufacturer records CE conformity in 2019. Disposable instruments avoid their reprocessing step; they do not eliminate all infection or cross-contamination risk.[8] |
| hinotori — Medicaroid | Eight-axis arms, software-defined pivot and an ergonomic surgeon cockpit with 3D viewing. | CE marking under MDR announced July 9, 2026, following earlier Japanese and selected Asian-market authorizations. Verify procedure-specific local labeling; this does not establish US FDA clearance.[9] |
| Revo-i — meerecompany | Master console, operation cart and vision cart; instrument portfolio includes graspers, needle holders and energy tools. | Korean platform with an evolving clinical footprint. Confirm the exact marketed model and local indication, rather than assuming lower cost or equivalence to another system.[10] |
| KANGDUO — Harbin Sagebot | Current SR2000 product information describes an open console, with an optional second console; other generations/configurations differ. | Correct manufacturer identity matters when interpreting older studies. The manufacturer announced CE certification under MDR in December 2025.[11] |
| MicroHand-S — WEGO | Manufacturer identifies the WG-NST600T system, with 3D visualization and flexible robotic arms. | Avoid transferring one generation's console, instrument or regulatory details to all MicroHand systems.[12] |
| Toumai — MicroPort MedBot | Multiport laparoscopic platform; the company also develops separate single-port and remote-surgery systems. | Company regulatory reporting records CE marking of the laparoscopic system in May 2024. Remote-surgery or single-port authorization must be checked separately.[13] |
The table is not a complete inventory of every country's approvals. Manufacturer sources establish identity and reported product/regulatory facts; they do not independently demonstrate superior clinical outcomes.
Da Vinci Generations and Feedback
The X should not be described as “Si-era arms on an Xi boom”: its instrument compatibility and patient-cart architecture are separate questions. Xi's rotating boom and positioning features should not be assumed on X. Likewise, the multiport instrument family is not uniformly one diameter or one reuse count: specialized Single-Site instruments, SP instruments and dedicated Force Feedback instruments have their own specifications.[1][2]
Da Vinci 5 Force Feedback transmits instrument-tip forces to the surgeon's hand controllers. This is different from the Force Bipolar grasper's selectable grip setting. Manufacturer-reported reductions in applied force from preclinical tissue-model studies do not by themselves establish better continence, potency, anastomotic durability or fewer clinical injuries.[2][14]
Use Robotic Instruments and the Energy Devices hub for actual model limitations. The latest local manual takes precedence over an old study's instrument list.
What Matters for Reconstructive Practice
| Decision | What to compare |
|---|---|
| Access and exposure | Target distance, docking space, patient positioning, assistant access, ability to reach multiple quadrants and safe emergency undocking. |
| Fine reconstruction | Instrument dimensions, wrist/elbow geometry, needle handling, motion scaling, visualization and the operator's training on that configuration. |
| Feedback | Whether the specific instrument transmits force, which forces it measures, and whether evidence concerns simulation, animal tissue or patient outcomes. |
| Energy and stapling | Compatible generators, tissue indications, availability of safe alternatives and instrument-specific limitations. |
| Reprocessing and supply | Validated reprocessing, use limits, sterile single-use components, availability, failure support and traceability. |
| Economics | Actual local acquisition/lease, service, consumables, operating time, staffing, training and utilization. A generic "$2 million" price or “cheaper competitor” label is not a current cost comparison. |
| Clinical evidence | Procedure, population, learning curve, comparator, follow-up and outcome definition. Technical feasibility is not comparative efficacy or long-term functional equivalence. |
These are evaluation criteria, not a recommendation to acquire a particular system. Port diameter alone cannot predict pain, cosmesis or complications, and an open console does not automatically establish better ergonomics for every operator.
Remote Surgery and Digital Assistance
Telesurgery demonstrations, video teleproctoring, automated camera functions and autonomous tissue manipulation are distinct capabilities. Confirm what a specific system actually does and what is authorized. Remote connectivity still requires a local surgical team, failure contingencies and an appropriate clinical/regulatory framework. Promising computer-vision or autonomous-suturing research should not be listed as routine functionality of every commercial platform.
References
1. Intuitive. Da Vinci X and Xi system brochures: instrument compatibility and system comparison. X brochure; Xi comparison.
2. Intuitive. Da Vinci instrument portfolio and Force Feedback technology. Instrument information.
3. Intuitive. Da Vinci SP surgical system. Manufacturer information.
4. Medtronic. FDA clearance of Hugo RAS for urologic procedures, December 3, 2025. Announcement; current US indications.
5. CMR Surgical. Versius FDA De Novo authorization, October 2024. Announcement; current US Versius Plus information and indications.
6. Distalmotion. Additional DEXTER gynecology indications, June 16, 2026. Manufacturer clearance announcement.
7. KARL STORZ. Acquisition of Asensus Surgical, August 22, 2024. Acquisition; current Senhance discontinuation notice and features.
8. avateramedical. System specifications and European conformity history. System; company regulatory history.
9. Medicaroid. Hinotori system and July 9, 2026 CE marking. Product information; CE announcement.
10. meerecompany. Revo-i system. Manufacturer information.
11. Harbin Sagebot. KANGDUO SR2000 system and December 2025 CE announcement. Manufacturer information.
12. WEGO. MicroHand-S, WG-NST600T. Manufacturer product information.
13. MicroPort MedBot. 2025 results announcement, published March 26, 2026: Toumai platform and regulatory history. Company exchange filing.
14. Intuitive. Preclinical Force Feedback study announcement, March 27, 2025. Research setting and claims.